W.-K. Hofmann

1.2k total citations
21 papers, 682 citations indexed

About

W.-K. Hofmann is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, W.-K. Hofmann has authored 21 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in W.-K. Hofmann's work include Acute Myeloid Leukemia Research (13 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Erythrocyte Function and Pathophysiology (3 papers). W.-K. Hofmann is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Erythrocyte Function and Pathophysiology (3 papers). W.-K. Hofmann collaborates with scholars based in Germany, France and United States. W.-K. Hofmann's co-authors include Eva Lengfelder, Daniel Nowak, Arnold Ganser, Oliver G. Ottmann, D. Hoelzer, Torsten Haferlach, G. Bug, Michael Heuser, E. M. Weissinger and Gudrun Göhring and has published in prestigious journals such as Blood, Annals of Oncology and Cellular and Molecular Life Sciences.

In The Last Decade

W.-K. Hofmann

20 papers receiving 669 citations

Peers

Countries citing papers authored by W.-K. Hofmann

Since Specialization

Citations

This map shows the geographic impact of W.-K. Hofmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.-K. Hofmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.-K. Hofmann more than expected).

Fields of papers citing papers by W.-K. Hofmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.-K. Hofmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.-K. Hofmann. The network helps show where W.-K. Hofmann may publish in the future.

Co-authorship network of co-authors of W.-K. Hofmann

This figure shows the co-authorship network connecting the top 25 collaborators of W.-K. Hofmann. A scholar is included among the top collaborators of W.-K. Hofmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.-K. Hofmann. W.-K. Hofmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia 2017 ·Annals of Oncology ·(unknown), Carsten Sticht, Markus Pfirrmann, Daniel Nowak, Alice Fabarius, Wolfgang Seifarth, Birgit Spieß, (unknown), Maria Pagoni, Maria Dimou, Jolanta Dengler, Cornelius F. Waller, Tim H. Brümmendorf, Andreas Burchert, (unknown), W.-K. Hofmann, F-X Mahon, Susanne Saußele	1
2	Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia 2017 ·Leukemia ·Mohamad Jawhar, Nicole Naumann, (unknown), J Score, (unknown), Björn Schneider, K.-A. Kreuzer, Michael Hallek, Hans G. Drexler, Joseph Chacko, (unknown), Alice Fabarius, Georgia Metzgeroth, W.-K. Hofmann, Andrew Chase, William Tapper, Andreas Reiter, Nicholas C.P. Cross	32
3	Azol-Resistenz bei Aspergillus fumigatus – Epidemiologie und Nachweis bei immunsupprimierten Patienten in Deutschland 2014 ·DMW - Deutsche Medizinische Wochenschrift ·Dieter Buchheidt, Birgit Spieß, Oliver A. Cornely, Maria J. G. T. Vehreschild, Axel Hamprecht, P.‐M. Rath, Jörg Steinmann, Uwe Groß, Oliver Bader, Melchior Lauten, Mark Reinwald, W.-K. Hofmann	3
4	Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia 2011 ·Leukemia ·Eva Lengfelder, W.-K. Hofmann, Daniel Nowak	132
5	296 Telomere shortening is associated with AML progression in patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide 2011 ·Leukemia Research ·(unknown), (unknown), W.-K. Hofmann, Hans Kreipe, Eva Hellström‐Lindberg, Aristoteles Giagounidis, Brigitte Schlegelberger	1
6	BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia 2010 ·Leukemia ·Sandra Heesch, Cornelia Schlee, Martín Neumann, Andrea Stroux, Andrea Kühnl, Stefan Schwartz, Torsten Haferlach, Nicola Goekbuget, D. Hoelzer, E. Thiel, W.-K. Hofmann, Claudia D. Baldus	31
7	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis 2010 ·Haematologica ·Felicitas Thol, E. M. Weissinger, J. Krauter, Katharina Wagner, Frédérik Damm, Manfred Wichmann, Gudrun Göhring, Christiane Schumann, G. Bug, Oliver G. Ottmann, W.-K. Hofmann, Brigitte Schlegelberger, Arnold Ganser, Michael Heuser	142
8	Prädiktion der perioperativen Mortalität bei Patienten mit fortgeschrittener Lebererkrankung und abdominalchirurgischen Eingriffen anhand unterschiedlicher Score- und Testsysteme 2008 ·Zeitschrift für Gastroenterologie ·W.-K. Hofmann, (unknown), Christian Moench, Wolf O. Bechstein, S Zeuzem	14
9	Discovery of epigenetically silenced genes in acute myeloid leukemias 2007 ·Leukemia ·Julian C. Desmond, Sophie Raynaud, Emily W. Y. Tung, W.-K. Hofmann, Torsten Haferlach, H. Phillip Koeffler	48
10	Aplastic Crisis as a Complication of Congenital Dyserythropoietic Anemia Type II 2006 ·Acta Haematologica ·H. Heimpel, (unknown), (unknown), W.-K. Hofmann, (unknown), B. Steinke, Jeremy Wechsler	4
11	Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia 2004 ·Annals of Hematology ·W.-K. Hofmann, Gerhard Heil, (unknown), Stephanie A. Wiebe, Oliver G. Ottmann, Lothar Bergmann, Klaus Hoeffken, J. Th. Fischer, Alexander Knuth, Karin Kolbe, Hans‐Joachim Schmoll, Wolfgang Langer, M. Westerhausen, (unknown), D. Hoelzer, Arnold Ganser	44
12	A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes 2004 ·Leukemia ·Michael Stadler, Ulrich Germing, (unknown), (unknown), R. Kuse, W.-K. Hofmann, Hubert Schrezenmeier, J Novotný, (unknown), Hartmut Eimermacher, Walter Verbeek, H. Kreipe, H. Heimpel, Carlo Aul, Arnold Ganser	100
13	Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus 2004 ·Cellular and Molecular Life Sciences ·Jindřich Činátl, (unknown), (unknown), Wolfgang Preiser, Jens‐Uwe Vogel, W.-K. Hofmann, Gabriele Bauer, Martin Michaelis, Holger F. Rabenau, H. W. Doerr	60
14	TGFβ-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS 2001 ·Leukemia ·Steffen Koschmieder, W.-K. Hofmann, Joachim Kunert, Stephan N. Wagner, K. Ballas, G. Seipelt, D. Hoelzer, Oliver G. Ottmann, Uwe Kalina	8
15	Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor α levels 2000 ·Annals of Hematology ·W.-K. Hofmann, G. Seipelt, Oliver G. Ottmann, Uwe Kalina, Steffen Koschmieder, (unknown), Norbert Frickhofen, Martine Klausmann, Paris S. Mitrou, D. Hoelzer	20
16	Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) 2000 ·Annals of Hematology ·Arnold Ganser, Gerhard Heil, G. Seipelt, W.-K. Hofmann, J. Th. Fischer, Wolfgang Langer, (unknown), Karin Kolbe, T. H. Ittel, N. Brack, H. G. Fuhr, (unknown), K. Höffken, Lothar Bergmann, D. Hoelzer	19
17	Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? 1999 ·Leukemia ·W.-K. Hofmann, Oliver G. Ottmann, D. Hoelzer	4
18	Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin 1998 ·Annals of Hematology ·G. Seipelt, W.-K. Hofmann, (unknown), Barbara Waßmann, Angelika Boehme, Oliver G. Ottmann, D. Hoelzer	8
19	174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML 1997 ·Leukemia Research ·Arnold Ganser, W.-K. Hofmann, (unknown), Oliver G. Ottmann, J. Th. Fischer, (unknown), (unknown), Wolfgang Langer, F. Herrmann, (unknown), A. Knuth, K. Höffken, K. Hoffmann, Christian G. Huber, Karin Kolbe, Hans‐Joachim Schmoll, (unknown), Bernd Hertenstein, D. Hoelzer	1
20	[Initial experiences in the treatment of virus-induced diarrheas in calves with interferon produced by genetic engineering]. 1985 ·PubMed ·W.-K. Hofmann, (unknown), K. Seeger	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact